138 related articles for article (PubMed ID: 14603160)
1. Practical management of liver transplant recipients for hepatitis C.
Saab S; Busuttil RW
Minerva Chir; 2003 Aug; 58(4):479-89. PubMed ID: 14603160
[TBL] [Abstract][Full Text] [Related]
2. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy).
Bahra M; Neumann UP; Jacob D; Langrehr JM; Berg T; Neuhaus R; Neuhaus P
Transplantation; 2007 Feb; 83(3):351-3. PubMed ID: 17297412
[TBL] [Abstract][Full Text] [Related]
3. Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
Satapathy SK; Fiel MI; Vanatta JM; Del Rio Martin J; Schiano TD
Exp Clin Transplant; 2013 Dec; 11(6):522-9. PubMed ID: 23901801
[TBL] [Abstract][Full Text] [Related]
4. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient.
Montalbano M; Pasulo L; Sonzogni A; Remuzzi G; Colledan M; Strazzabosco M
J Clin Gastroenterol; 2007 Feb; 41(2):216-20. PubMed ID: 17245223
[TBL] [Abstract][Full Text] [Related]
5. Therapy of hepatitis C: from empiricism to eradication.
Pawlotsky JM
Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
[TBL] [Abstract][Full Text] [Related]
6. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
Mukherjee S; Lyden E
Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
[TBL] [Abstract][Full Text] [Related]
7. [Antiviral treatment in liver cirrhosis due to hepatitis C virus].
Martínez-Bauer E; Forns X
Gastroenterol Hepatol; 2003 May; 26(5):303-6. PubMed ID: 12732104
[No Abstract] [Full Text] [Related]
8. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
[TBL] [Abstract][Full Text] [Related]
9. Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir.
Marquez-Azalgara V; Hussaini T; Erb SR; Yoshida EM
Ann Hepatol; 2014; 13(5):565-7. PubMed ID: 25152991
[TBL] [Abstract][Full Text] [Related]
10. News and challenges in the treatment of hepatitis C in liver transplantation.
Coilly A; Roche B; Duclos-Vallée JC; Samuel D
Liver Int; 2016 Jan; 36 Suppl 1():34-42. PubMed ID: 26725895
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of chronic hepatitis C].
Fehér J; Lengyel G
Orv Hetil; 2004 May; 145(20):1065-7. PubMed ID: 15202329
[No Abstract] [Full Text] [Related]
13. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
14. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
15. PEG-IFN and ribavirin re-treatment of HCV-1b cirrhosis non responder to conventional combination therapy.
Morisco F; Amoruso D; Stroffolini T; Caporaso N
Dig Liver Dis; 2008 May; 40(5):391-2. PubMed ID: 18291731
[No Abstract] [Full Text] [Related]
16. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.
O'Leary JG; McKenna GJ; Klintmalm GB; Davis GL
Liver Transpl; 2013 Apr; 19(4):463-5. PubMed ID: 23408534
[No Abstract] [Full Text] [Related]
17. Long-term effects of interferon-based therapy for chronic hepatitis C.
Yu ML; Huang CF; Dai CY; Huang JF; Chuang WL
Oncology; 2007; 72 Suppl 1():16-23. PubMed ID: 18087178
[TBL] [Abstract][Full Text] [Related]
18. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
[TBL] [Abstract][Full Text] [Related]
19. Changing faces-natural course and treatment of hepatitis C after liver transplantation.
Bahr MJ; Manns MP
J Hepatol; 2004 Apr; 40(4):699-701. PubMed ID: 15030989
[No Abstract] [Full Text] [Related]
20. Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.
Westin J; Hellstrand K; Alsiö A; Ydreborg M; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Verhey-Hart E; Lagging M
Hepatology; 2007 May; 45(5):1333-4; author reply 1334. PubMed ID: 17464982
[No Abstract] [Full Text] [Related]
[Next] [New Search]
